Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma

Shanthi Marur, James Eliason, Lance K. Heilbrun, Brenda Dickow, Daryn W. Smith, Karen Baranowski, Samir Alhasan, Ulka Vaishampayan

Research output: Contribution to journalArticle

Abstract

Objectives: To evaluate the toxicity and efficacy of capecitabine and weekly docetaxel in a phase II clinical trial. Methods: Eligibility included metastatic renal cancer with a maximum of 2 prior regimens, performance status of 0-2, and adequate renal, hepatic, and bone marrow function. Docetaxel was administered intravenously at a dose of 36 mg/m2 weekly on days 1, 8, and 15 of a 28- day cycle and capecitabine was administered orally at a dose of 1800 mg/m2 from days 5-18. Toxicity was assessed on days 1, 8, and 15 of each cycle, and response was evaluated every 2 cycles. Results: Twenty-five patients, 19 white and 6 African American, were enrolled on this phase II trial. The median age was 60 years (range: 39-75 years). Eighteen patients had clear cell histology, 7 had papillary, sarcomatoid, or chromophobe histology. Thirteen had liver/bone metastases and 13 had ≥2 of the Memorial Sloan-Kettering Cancer Center prognostic risk factors. Twelve patients received prior immunotherapy. A total of 93 cycles were administered; median of 3 cycles and range from 0-10 cycles. The therapy was well tolerated. No treatment-related mortality was observed and 2 treatment-related hospitalizations for nausea, diarrhea, and dehydration occurred. Ten patients had stable disease. The median time to progression was 1.7 months and median survival was 11.1 months. Conclusions: The combination of capecitabine and docetaxel was well tolerated in metastatic renal cancer. Clinical activity was predominantly noted in non-clear cell histology in which chemotherapy would be worthy of future investigation.

Original languageEnglish (US)
Pages (from-to)898-902
Number of pages5
JournalUrology
Volume72
Issue number4
DOIs
StatePublished - Oct 2008
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Marur, S., Eliason, J., Heilbrun, L. K., Dickow, B., Smith, D. W., Baranowski, K., Alhasan, S., & Vaishampayan, U. (2008). Phase II Trial of Capecitabine and Weekly Docetaxel in Metastatic Renal Cell Carcinoma. Urology, 72(4), 898-902. https://doi.org/10.1016/j.urology.2008.05.032